Tmunity Signs an Exclusive Research Agreement with the University of California to Advance TCR Therapies for Pediatric Cancers


  • Tmunity & University of California enter into an exclusive research agreement for the improvement of TCR therapies for rare diseases including DIPG in pediatric patients. Tmunity will be responsible for development & commercialization of the H3.3K27M TCR therapy
  • The focus of the collaboration is to strengthen Tmunity’s portfolio by developing therapies for diffuse intrinsic pontine glioma (DIPG) targeting H3.3K27M i.e, K27M mutation in the H3.3 histone
  • Tmunity’s portfolio includes T cell therapy platforms, T cell receptors, regulatory T cells, gene transfer, allogeneic T cells and bionic T cells & CAR-T programs used for activating or suppressing immunity

Click here to read full press release/ article | Ref: Tmunity | Image: Pinterest